CN114072175A - 治疗肿瘤的物质和方法 - Google Patents
治疗肿瘤的物质和方法 Download PDFInfo
- Publication number
- CN114072175A CN114072175A CN202080047643.5A CN202080047643A CN114072175A CN 114072175 A CN114072175 A CN 114072175A CN 202080047643 A CN202080047643 A CN 202080047643A CN 114072175 A CN114072175 A CN 114072175A
- Authority
- CN
- China
- Prior art keywords
- ctla4
- antibody
- amino acid
- binding protein
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本申请公开了CTLA4结合蛋白用于治疗肿瘤的方法和用途，其中所述CTLA4结合蛋白特异性结合CTLA4且不与CTLA4的配体竞争结合所述CTLA4。本申请所述的CTLA4结合蛋白能够有效地抑制肿瘤生长。
Description
PCT国内申请，说明书已公开。
Claims (47)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/094751 | 2019-07-04 | ||
| CN2019094751 | 2019-07-04 | ||
| PCT/CN2020/100232 WO2021000953A1 (zh) | 2019-07-04 | 2020-07-03 | 治疗肿瘤的物质和方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114072175A true CN114072175A (zh) | 2022-02-18 |
Family
ID=74101201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080047643.5A Pending CN114072175A (zh) | 2019-07-04 | 2020-07-03 | 治疗肿瘤的物质和方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220251207A1 (zh) |
| EP (1) | EP3995147A4 (zh) |
| JP (1) | JP2022539260A (zh) |
| CN (1) | CN114072175A (zh) |
| WO (1) | WO2021000953A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022378755A1 (en) * | 2021-10-28 | 2024-06-06 | Monash University | Variant ctla4 proteins |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103833851A (zh) * | 2014-03-14 | 2014-06-04 | 东南大学 | 针对于载脂蛋白a1的单域抗体及其应用 |
| CN107400166A (zh) * | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | 针对ctla4的单域抗体及其衍生蛋白 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2783517B1 (fr) | 1998-09-22 | 2001-02-09 | Oreal | Nouveaux derives de l'acide 10-hyroxy-2-decenoique et utilisation dans une composition destinee a favoriser la desquamation de la peau, et composition le comprenant |
| CN106397592A (zh) | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| WO2018068201A1 (en) * | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| KR20200024905A (ko) * | 2017-07-04 | 2020-03-09 | 큐어백 아게 | 신규 핵산 분자 |
-
2020
- 2020-07-03 JP JP2022500131A patent/JP2022539260A/ja active Pending
- 2020-07-03 EP EP20835357.3A patent/EP3995147A4/en active Pending
- 2020-07-03 CN CN202080047643.5A patent/CN114072175A/zh active Pending
- 2020-07-03 US US17/624,795 patent/US20220251207A1/en active Pending
- 2020-07-03 WO PCT/CN2020/100232 patent/WO2021000953A1/zh unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103833851A (zh) * | 2014-03-14 | 2014-06-04 | 东南大学 | 针对于载脂蛋白a1的单域抗体及其应用 |
| CN107400166A (zh) * | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | 针对ctla4的单域抗体及其衍生蛋白 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3995147A1 (en) | 2022-05-11 |
| WO2021000953A1 (zh) | 2021-01-07 |
| JP2022539260A (ja) | 2022-09-07 |
| EP3995147A4 (en) | 2023-08-16 |
| US20220251207A1 (en) | 2022-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7450592B2 (ja) | 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ | |
| EP3511346A1 (en) | Anti-ctla4 and anti-pd-1 bifunctional antibody, pharmaceutical composition thereof and use thereof | |
| KR101719118B1 (ko) | 항-ox40 항체 및 그의 용도 | |
| KR20190050994A (ko) | 항-pd1 단일클론 항체, 이의 약제학적 조성물 및 이의 용도 | |
| JP2020503245A (ja) | 抗ヒト４−１ｂｂ抗体およびその使用 | |
| KR20210102941A (ko) | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 | |
| KR20210142638A (ko) | Cd3 항원 결합 단편 및 이의 응용 | |
| CN111050792A (zh) | 抗lag-3抗体及其用途 | |
| WO2021219048A1 (zh) | 一种靶向nkg2a和pd-l1的双特异性抗体及应用 | |
| EP4223778A1 (en) | Anti-claudin18.2 and cd3 bispecific antibody and use thereof | |
| JP2022505925A (ja) | 抗ｔｉｍ－３抗体 | |
| KR20220101126A (ko) | 항-Siglec-9 항체 분자 | |
| CN114072175A (zh) | 治疗肿瘤的物质和方法 | |
| EP4389767A1 (en) | Monoclonal antibody targeting sirp? and use thereof | |
| WO2023034963A2 (en) | Combinations of immunotherapies and uses thereof | |
| KR20240005809A (ko) | 항-il-27 항체 및 이의 용도 | |
| JP2020508636A (ja) | ＩＦＮ−γ誘導性制御性Ｔ細胞転換性抗癌（ＩＲＴＣＡ）抗体およびその使用 | |
| US20240141070A1 (en) | Ox40/pd-l1 bispecific antibody | |
| TW202222834A (zh) | Ｐｄ－ｌ１抗體及其應用 | |
| WO2018119288A1 (en) | Anti-human cxcr3 antibodies for treatment of vitiligo | |
| WO2022188865A1 (zh) | 结合人TGFβ和PD-L1的双功能分子及其应用 | |
| WO2024085182A1 (ja) | Ｔ細胞性腫瘍の治療剤 | |
| WO2024001641A1 (zh) | Cd101的抗体及其用途 | |
| TWI809615B (zh) | 抗ｐｄ-ｌ１抗體、編碼其的核酸、包含其的載體、細胞、藥物組合物及其用途 | |
| EP4293047A1 (en) | Anti-pd-l1 antibody and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40063855 Country of ref document: HK |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |